BELFOR
22.6.2022 17:39:12 CEST | Business Wire | Pressemeddelelse
BELFOR, verdens største skadeservicevirksomhed og SSG, førende på det skandinaviske marked inden for skadesanering og genopbygning, har slået sig sammen for at styrke vores kundeservice i Danmark, Norge og Sverige.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20220622005634/da/
BELFOR har nu mere end 12.500 medarbejdere og 500+ lokationer i hele verden. Vi dækker alle led, når det kommer til genopbygning efter en skade. Vi vurderer skaden, igangsætter nødvendige foranstaltninger, og vi sørger for renovering og genopbygning, uanset skadens omfang.
SSG Group tilbyder bl.a. skadeservice, renovering og genopbygning og har 980 medarbejdere, fordelt på 57 lokationer i Danmark, Sverige og Norge.
"Med SSG udvider vi vores dygtige og erfarne teams med gode folk, øger vores servicekapacitet og optimerer vores responstider for vores nationale og internationale kunder", udtaler Elvir Kolak, CEO for BELFOR Europe.
"Denne transaktion betyder et enormt løft for vores organisationer i Danmark, Norge og Sverige. Ved at kombinere BELFORS tekniske kompetencer med vores serviceportefølje åbner vi for nye udviklingsmuligheder for vores medarbejdere", tilføjer Carsten Fensholt, CEO for SSG Group.
"Vi er glade for at byde SSG velkommen i BELFOR-familien, og vi glæder os til at medvirke til deres fremtidige vækst. SSG beskæftiger fantastiske medarbejdere og har stort fokus på kunderne – og er derfor et perfekt match for os! Vi er stolte over at få dem ombord. Hos BELFOR er vores vækstplaner ambitiøse, og vi leder aktivt efter gode virksomheder, der kan tilslutte sig BELFOR-familien – både i Skandinavien og resten af Europa", afslutter Sheldon Yellen, global CEO hos BELFOR.
Fremover vil BELFOR være Danmarks førende skadeservicevirksomhed med tilføjelsen af 650 nye medarbejdere. Opkøbet af SSG er et stort skridt på vejen mod en større tilstedeværelse i Skandinavien, som startede med erhvervelsen af det danske skadeservicefirma, Røsva, efterfulgt af Rølund i 2021.
OM BELFOR
BELFOR er førende på det globale marked inden for skadeservice. Med mere end 40 års erfaring kan vi hos BELFOR tilbyde at hjælpe dig igennem hele dit skadesforløb, lige fra vurdering af skaden, til renovering og genopbygning. Det betyder bl.a., at vi er den foretrukne partner både for forsikringsselskaber samt kommercielle og private kunder. Med SSG under fanen har BELFOR nu mere end 12.500 ansatte og 500 lokationer i 57 lande. Vi er klar til at hjælpe vores kunder 24 timer i døgnet, 365 dage om året, uanset hvor store og komplekse skaderne er.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220622005634/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release
Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release
Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum